0001571049-16-020055.txt : 20161121 0001571049-16-020055.hdr.sgml : 20161121 20161121162058 ACCESSION NUMBER: 0001571049-16-020055 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161121 DATE AS OF CHANGE: 20161121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTH DISCOVERY CORP CENTRAL INDEX KEY: 0001141788 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 743002154 STATE OF INCORPORATION: 2Q FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-62216 FILM NUMBER: 162010542 BUSINESS ADDRESS: STREET 1: 4243 DUNWOODY CLUB DRIVE STREET 2: SUITE #202 CITY: ATLANTA STATE: GA ZIP: 30350 BUSINESS PHONE: (678)336-5300 MAIL ADDRESS: STREET 1: 4243 DUNWOODY CLUB DRIVE STREET 2: SUITE #202 CITY: ATLANTA STATE: 2Q ZIP: 31401 FORMER COMPANY: FORMER CONFORMED NAME: DIRECT WIRELESS COMMUNICATIONS INC DATE OF NAME CHANGE: 20010531 10-Q 1 t1600733_10q.htm FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2016

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transaction period from _____________ to _____________

Commission file number 333-62216

HEALTH DISCOVERY CORPORATION

(Exact name of registrant as specified in its charter)

Georgia
(State or other jurisdiction of incorporation or organization)

74-3002154
(IRS Employer Identification No.)

4243 Dunwoody Club Drive

Suite 202

Atlanta, Georgia 30350

(Address of principal executive offices)

(678) 336-5300

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year,

if changed since the last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for at least the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):

Large Accelerated Filer	¨	Non-Accelerated Filer	¨

		(do not check if a smaller reporting company)

Accelerated Filer	¨	Smaller Reporting Company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

Class:	Outstanding as of November 21, 2016

Common Stock, no par value	271,718,989

Series A Preferred Stock	0

Series B Preferred Stock	0

Series C Preferred Stock	30,000,000

TABLE OF CONTENTS

PART I — FINANCIAL STATEMENTS			2

	Item 1.	Unaudited Financial Statements	2

		Balance Sheets	2

		Statements of Operations	3

		Statements of Cash Flows	4

		Notes to Financial Statements	5

	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	11

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16

	Item 4.	Controls and Procedures.	16

PART II — OTHER INFORMATION			17

	Item 1.	Legal Proceedings	17

	Item 1A.	Risk Factors	17

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17

	Item 3.	Defaults Upon Senior Securities	18

	Item 4.	Mine Safety Disclosures	18

	Item 5.	Other Information.	18

	Item 6.	Exhibits.	18

SIGNATURES			18

iii

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

HEALTH DISCOVERY CORPORATION

Balance Sheets

(unaudited)

	September 30,			December 31,
	2016			2015
Assets
Current Assets
Cash	$	183,451		$	417,208
Investment in Available For Sale Securities (Note G)		148,074			141,978

Total Current Assets		331,525			559,186

Equipment, Less Accumulated Depreciation of $60,885 and $60,690 as of September 30, 2016 and December 31, 2015, respectively		-			195

Other Assets
Patents, Less Accumulated Amortization of $3,241,769 and $3,044,729 as of September 30, 2016 and December 31, 2015, respectively		744,026			941,066


Total Assets	$	1,075,551		$	1,500,447

Liabilities and Stockholders' Equity

Current Liabilities
Accounts Payable - Trade	$	140,166		$	37,633
Dividends Payable		206,637			206,637
Deferred Revenue		43,388			43,388
Common Stock Warrants Liability (Note D)		-			339,268

Total Current Liabilities		390,191			626,926

Long Term Liabilities
Deferred Revenue		72,312			104,853

Total Liabilities		462,503			731,779

Stockholders' Equity
Series C Preferred Stock, Convertible, 45,000,000 Shares Authorized; 30,000,000 Issued and Outstanding September 30, 2016 and December 31, 2015		900,000			560,732
Common Stock, No Par Value, 450,000,000 Shares Authorized; 271,718,989 Shares Issued and Outstanding September 30, 2016; 268,718,989 Shares Issued and Outstanding December 31, 2015		28,873,471			27,410,930
Accumulated Deficit		(29,160,423	)		(27,202,994	)

Total Stockholders' Equity		613,048			768,668

Total Liabilities and Stockholders' Equity	$	1,075,551		$	1,500,447

See accompanying notes to financial statements.

HEALTH DISCOVERY CORPORATION

Statements of Operations

(unaudited)

For the Three and Nine Months Ended September 30, 2016 and 2015

	Three Months			Three Months			Nine Months			Nine Months
	Ended			Ended			Ended			Ended
	September 30,			September 30,			September 30,			September 30,
	2016			2015			2016			2015

Revenues:
Licensing and Development	$	10,847		$	12,050		$	32,665		$	33,754

Operating Expenses:
Depreciation and Amortization		65,680			65,875			197,234			197,770
Professional and Consulting Fees		51,848			30,965			173,274			129,377
Legal Fees		6,225			9,000			21,225			37,357
Research and Development Fees		9,000			9,000			27,000			31,813
Compensation		56,179			48,328			233,035			142,665
Other General and Administrative Expenses		42,514			33,438			147,811			116,112
Total Operating Expenses		231,446			196,606			799,579			655,094

Loss From Operations		(220,599	)		(184,556	)		(766,914	)		(621,340	)

Other Income (Expense)
Unrealized Gain (Loss) on Available for Sale Securities (Note G)		3,240			(17,917	)		6,096			(160,706	)
Realized Gain on Available for Sale Securities (Note G)		-			27,192			-			232,937
Other Expense – Change in Warrants Liability (Note D)		-			-			(1,196,612	)		-
Forgiveness on Payables (Note H)		-			121,503			-			121,503
Settlement Expense		-			-			-			(17,693	)
Other Income (Expense), net		3,240			130,778			(1,190,516	)		176,041

Net Loss		(217,359	)		(53,778	)		(1,957,430	)		(445,299	)

Net Loss Attributable to Common Stockholders	$	(217,359	)	$	(53,778	)	$	(1,957,430	)	$	(445,299	)

Weighted Average Outstanding Shares – basic and diluted		271,718,989			266,052,322			271,052,322			265,163,433

Net Loss Per Share – basic and diluted	$	(0.0008	)	$	(0.0002	)	$	(0.0072	)	$	(0.0017	)

See accompanying notes to financial statements.

HEALTH DISCOVERY CORPORATION

Statements of Cash Flows

(unaudited)

For the Nine Months Ended September 30, 2016 and 2015

	2016			2015
Cash Flows From Operating Activities:
Net Loss	$	(1,957,430	)	$	(445,299	)
Adjustments to Reconcile Net Loss to Net Cash
Used in Operating Activities:
Stock-based Compensation for Employees		102,233			11,512
Stock-based Compensation for Directors and Consultants		73,698			39,700
Realized Gain on Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G)		-			(232,937	)
Unrealized (Gain) Loss on Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G)		(6,096	)		160,706
Increase in Warrants Liability (Note D)		1,196,612			-
Depreciation and Amortization		197,234			197,770
Decrease in Accounts Receivable		-			1,969
Decrease in Deferred Revenue		(32,541	)		(32,541	)
Increase (Decrease) in Accounts Payable – Trade		102,533			(98,639	)
Forgiveness on Accounts Payable – Trade		-			(121,503	)
Increase in Available for Sale Securities		-			(1,294	)

Net Cash Used in Operating Activities		(323,757	)		(520,556	)

Cash Flows From Investing Activities:
Proceeds from Sale of Available for Sale Securities (Note G)		-			331,465
Net Cash Provided by Investing Activities		-			331,465

Cash Flows From Financing Activities:
Proceeds from Common Stock Issuance		90,000			120,000
Proceeds from Series C Preferred Stock Issuance		-			568,000
Net Cash Provided by Financing Activities		90,000			688,000

Net (Decrease) Increase in Cash		(233,757	)		498,909

Cash, at Beginning of Period		417,208			7,642

Cash, at End of Period	$	183,451		$	506,551

See accompanying notes to financial statements.

HEALTH DISCOVERY CORPORATION

Notes to Financial Statements (unaudited)

Note A - BASIS OF PRESENTATION

Health Discovery Corporation (the “Company”) is a biotechnology-oriented company that has acquired patents and has patent pending applications for certain machine learning tools, primarily pattern recognition techniques using advanced mathematical algorithms to analyze large amounts of data thereby uncovering patterns that might otherwise be undetectable. Such machine learning tools are currently in use for diagnostics and drug discovery, but are also marketed for other applications. The Company licenses the use of its patent protected technology and may provide services to develop specific learning tools under development agreements or to sell to third parties.

The accounting principles followed by the Company and the methods of applying these principles conform with accounting principles generally accepted in the United States of America (GAAP). In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts in the financial statements. Actual results could differ significantly from those estimates.

The interim financial statements included in this report are unaudited but reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial position and results of operations for the interim periods presented. All such adjustments are of a normal recurring nature. The results of operations for the nine month period ended September 30, 2016 are not necessarily indicative of the results of a full year’s operations and should be read in conjunction with the financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

Note B – REVENUE RECOGNITION

Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements. These arrangements are generally governed by contracts that dictate responsibilities and payment terms. The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled. If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.

The Company treats the incremental direct cost of revenue arrangements, which consists principally of employee bonuses, as deferred charges and these incremental direct costs are amortized to expense using the straight-line method over the same term as the related deferred revenue recognition.

Deferred revenue represents the unearned portion of payments received in advance for licensing and development agreements. The Company had total unearned revenue of $115,700 as of September 30, 2016. Unearned revenue of $43,388 is recorded as current and $72,312 is classified as long-term.

Note C - NET (LOSS) INCOME PER SHARE

Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss in all periods presented, potentially dilutive shares are not included in the calculation of diluted EPS, as those shares would create an anti-dilutive result.

Note D - STOCK-BASED COMPENSATION and other EQUITY BASED PAYMENTS

Stock-based compensation expense included in our net loss for the three months and nine months ended September 30, 2016 was $35,163 and $175,931, respectively, for stock options granted to employees, directors, and consultants. Stock-based compensation expense included in our net loss for the three months and nine months ended September 30, 2015 was $17,071 and $51,212, respectively.

As of September 30, 2016, there was $192,993 of unrecognized cost related to stock option grants. The cost is to be recognized over the remaining vesting periods that average approximately 2.25 years.

HEALTH DISCOVERY CORPORATION

Notes to Financial Statements (unaudited), continued

Note D - STOCK-BASED COMPENSATION and other EQUITY BASED PAYMENTS, continued

In connection with their election to the Board of Directors, on May 17, 2016, the Company granted to Mr. Henry Kaplan, Mr. Kevin Kowbel, Mr. George McGovern, and Mr. William Quirk each an option to purchase 1,500,000 shares of the Company’s common stock. The options for Messrs. Kaplan, Kowbel, McGovern and Quirk vest 250,000 shares every six months, have an exercise price of $0.035, and expire on May 17, 2026. The fair value of each option granted is $0.0265 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.89%, an expected life of 5 years, and volatility of 102%. The aggregate computed fair value of these options is $158,756, and this amount will be charged as an expense over the three-year vesting period.

Additionally, in recognition of his leadership as Chairman of the Board of Directors and CEO, on May 17, 2016, the Company granted to Mr. Kevin Kowbel an option to purchase 3,000,000 shares of the Company’s common stock. The options for Mr. Kowbel vest immediately, have an exercise price of $0.035, and expire on May 17, 2026. The fair value of each option granted is $0.0265 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.89%, an expected life of 5 years, and volatility of 102%. The aggregate computed fair value of these options is $79,519, and this amount was charged as an expense during the second quarter of 2016.

On February 8, 2016, the Company granted options to purchase 5,000,000 shares of the Company’s common stock to a group of employees and consultants in recognition of their efforts to lower the Company’s monthly expenditures and compensation and their continuing contributions to the Company. The options vest over a two-year period, have an exercise price of $.03, and expire on February 8, 2026. Within the group of 5,000,000 options, the Company’s Vice President, Mark A. Moore, Ph.D., received an option to purchase 500,000 shares of the Company’s common stock and the Company’s Senior Vice President, Hong Zhang, Ph.D., received an option to purchase 1,250,000 shares of the Company’s common stock. The fair value of each option granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.99%, an expected life of 5 years, and volatility of 96%. The aggregate computed fair value of these options is $109,271, and this amount will be charged as an expense over the two-year vesting period. Because at the time of issuance, these options exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company needed to increase the authorized shares of common stock in order to satisfy these options. The shareholders of the Company approved this increase in authorized shares on May 17, 2016.

In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2015, the Company had issued a total of 30,000,000 preferred shares. The Series C Preferred Shares were fully subscribed in the third quarter 2015. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were issued during the three months ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. Because at the time of issuance, these warrants exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company needed to increase the authorized shares of common stock in order to satisfy these options. The shareholders of the Company approved this increase in authorized shares on May 17, 2016. The fair value of each warrant granted was $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%.

During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of March 31, 2016, 7,000,000 shares of this offering were sold. During the three and six month periods ended March 31, 2016, the Company sold 3,000,000 of these shares and received $90,000 in proceeds. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants were issued during the three months ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. Because at the time of issuance, these warrants exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company needed to increase the authorized shares of common stock in order to satisfy these options. The shareholders of the Company approved this increase in authorized shares on May 17, 2016. The fair value of each warrant granted was $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%.

HEALTH DISCOVERY CORPORATION

Notes to Financial Statements (unaudited) , continued

Note D - STOCK-BASED COMPENSATION and other EQUITY BASED PAYMENTS, continued

Furthermore, as a result of the Company issuing options and warrants which exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company recorded an increase in the common stock warrants liability during the first quarter of 2016 of $940,812 and $255,800 during the second quarter of 2016.

As previously disclosed above, the Company had issued options and warrants which exceeded the amount of common shares available if the holders exercised all of the previously issued outstanding options and warrants. This created a common stock warrant liability for the Company. During the first quarter, based upon the trading price of the Company’s common stock, this liability increased by $940,812 and during the second quarter of 2016 increased by $1,196,612. At the Annual Shareholder Meeting of the Company held on May 17, 2016, the shareholders approved an increase to the authorized shares of common and preferred stock. As a result, the Company has enough common stock available if the holders exercised all of the previously issued outstanding options and warrants. This resulted in there no longer being a common stock warrant liability for the Company. With the reduction in the common stock warrant liability, the Company increased the common stock value within the balance sheet.

As of September 30, 2016, there were 100,750,000 option and warrant shares outstanding with a weighted average exercise price of $0.033. The following schedule summarizes combined stock option and warrant information as of September 30, 2016:

Exercise Prices	Number Outstanding		Weighted- Average Remaining Contractual Life (years)		Number Exercisable		Weighted Average Remaining Contractual Life (years) of Exercisable Options and Warrants
$0.027		3,000,000		6.75		3,000,000		6.75
$0.030		72,000,000		9.25		68,250,000		9.25
$0.035		9,000,000		9.75		3,000,000		9.75
$0.036		7,750,000		7.00		6,833,335		7.00
$0.040		1,000,000		1.25		1,000,000		1.25
$0.050		1,000,000		1.25		1,000,000		1.25
$0.060		7,000,000		9.50		7,000,000		9.50
Total		100,750,000				90,083,335

The weighted average remaining life of all outstanding warrants and options at September 30, 2016 are 9.35 years. The aggregate intrinsic value of all options and warrants outstanding and exercisable as of September 30, 2016 was $392,400, based on the market closing price of $0.0351 on September 30, 2016, less exercise prices.

Note E - PATENTS

The Company has acquired and developed a group of patents related to biotechnology and certain machine learning tools used for diagnostic and drug discovery. Legal costs associated with patent acquisitions and the application processes for new patents are also capitalized as patent assets. The Company has recorded as other assets $744,026 in patents and patent related costs, net of $ 3,241,769 in accumulated amortization, at September 30, 2016.

Amortization charged to operations for the three months and nine months ended September 30, 2016 and 2015 was $65,680 and $197,039 in both years. Estimated amortization expense for the next three years, including 2016, is $262,720 per year. Estimated amortization expense for the fourth year is $152,906 and no amortization expense for the fifth year.

HEALTH DISCOVERY CORPORATION

Notes to Financial Statements (unaudited), continued

Note F – STOCKHOLDERS’ EQUITY

Series C Preferred Stock

In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2015, the Company had issued a total of 30,000,000 preferred shares. The Series C Preferred Shares were fully subscribed in the third quarter of 2015. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire. The fair value of each warrant granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%. The aggregate fair value of these warrants is $656,380.

The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.

Each share of Series C Preferred Stock may be converted into one share of Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. If the Company were to be dissolved, the Series C Preferred Stock receives preferential treatment over Common Stock.

During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of September 30, 2016, 7,000,000 shares of this offering have been sold. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire. The fair value of each warrant granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%.

Note G – INVESTMENT IN AVAILABLE FOR SALE SECURITIES

The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, as it relates to its shares held in NeoGenomics’ common stock that were acquired resulting from the NeoGenomics Master License Agreement executed on January 6, 2012. Management made the election for the fair value option related to this investment because it believes the fair value option for the NeoGenomics common stock provides a better measurement from which to compare financial statements from reporting period to reporting period. No other financial assets or liabilities are fair valued using the fair value option.

The Company’s investment in NeoGenomics’ common stock is recorded on the accompanying balance sheets under the caption Investment in Available for Sale Securities. The carrying value of this investment on the date of acquisition approximated $1,945,000. The change in fair value from December 31, 2015 to September 30, 2016 is an unrealized gain of $6,096 for the remaining 18,000 shares held and is classified as other expense under the caption Unrealized Gain (Loss) on Available for Sale Securities in the accompanying statements of operations. There are three levels of investments in the fair value hierarchy that assesses a company's assets based on the degree of certainty around the asset's underlying value. A Level 1 asset can be valued with certainty because they are liquid and have clear market prices. At the other end of the spectrum, Level 3 assets are illiquid and estimating their value requires inputs that are unobservable and reflect significant management assumptions. The Company classifies its investment as an available for sale security presented as a trading security on the balance sheets and the fair value is considered a Level 1 investment in the fair value hierarchy. The September 30, 2016 fair value of the investment of $148,074 is for the remaining shares held and is calculated using the closing stock price of the NeoGenomics common stock at the end of the reporting period.

HEALTH DISCOVERY CORPORATION

Notes to Financial Statements (unaudited) , continued

Note G – INVESTMENT IN AVAILABLE FOR SALE SECURITIES, continued

As of September 30, 2016 and December 31, 2015, the Company held 18,000 shares of NeoGenomics stock.

Note H – COMMITMENTS AND CONTINGENCIES

On July 17, 2013, the Company received a Civil Investigative Demand (the "Demand") from the Federal Trade Commission of the United States of America (the "FTC") relating to the Company's MelApp software application. In the Demand, the FTC requested information relating to potentially unfair or deceptive acts or practices related to (i) false advertising and (ii) consumer privacy and data security, in violation of Trade Commission Act, 15 U.S.C. Sections 45 and 42.

On February 23, 2015, the FTC notified the Company of its approval, by a vote of 4-1, to accept an Agreement Containing Consent Order (“Agreement”). This Agreement was for settlement purposes only. The Company neither admitted nor denied any of the allegations, except as specifically stated in the Agreement. The Company believed the effort to contest this matter with the FTC would require funds greater than the Company had at its disposal.

The Agreement does, among other things, bar the Company from claiming that any device detects or diagnoses melanoma or its risk factors, or increases users’ chances of early detection, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. The Agreement also prohibits the Company from making any other misleading or unsubstantiated claims about a device’s health benefits or efficacy, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. Finally, the Company was required to pay $17,693 to the FTC, which was accrued during the three month period ended March 31, 2015. This amount is included as Settlement Expense in the accompanying statements of operations for the nine-month period ended September 30, 2015.

The Company’s balance sheet for the year ended December 31, 2014 reflected an accrued liability of approximately $239,910 for professional services. In an effort to conserve cash, the Company worked with several of the vendors regarding a portion of this amount by negotiating with the service providers regarding potential reduction of the amount billed. During the quarter ended September 30, 2015, the Company and the service providers negotiated the amounts owed and as a result, the Company recorded a decrease in accounts payables of $121,503. During the period ended September 30, 2016 there was no forgiveness on payables.

The Company is subject to various claims primarily arising in the normal course of business. Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

Note I – FINANCIAL CONDITION AND GOING CONCERN

The Company has prepared its financial statements on a “going concern” basis, which presumes that it will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

The Company’s ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing and successfully bringing the Company’s technologies to the market. The outcome of these matters cannot be predicted at this time. The Company’s financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should the Company be unable to continue in business.

If the going concern assumption was not appropriate for the Company’s financial statements then adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments may be material.

At September 30, 2016, the Company had $183,451 of cash on hand along with its investment in NeoGenomics stock classified as available for sale securities worth $148,074. Also, at September 30, 2016, the Company had $390,191 in current liabilities. As a result, the Company estimates cash will be depleted by the end of first quarter 2017 if the Company does not generate sufficient cash to support operations.

The Company’s plan to have sufficient cash to support operations is comprised of generating revenue through finding new opportunities to license its technology, providing services related to those patents, selling its NeoGenomics stock, and obtaining additional equity or debt financing.

The Company is currently in discussions with NeoGenomics to modify the current agreement between the two companies. One of the goals for these discussions is to obtain quarterly payments from NeoGenomics that would help cover monthly expenses.

Additionally, the Company is attempting to encourage the Series C Preferred Stockholders to exercise some or all of their warrants in order to help fund the operations of the Company.

While the Company believes these efforts will create a profitable future, there is no guarantee the Company will be successful in these efforts.

HEALTH DISCOVERY CORPORATION

Notes to Financial Statements (unaudited), continued

Note J – RECENT ACCOUNTING PRONOUNCEMENTS

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards (“ASU”) 2016-02, Leases. This standard update was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including for operating leases, on the balance sheet and disclosing key information about leasing arrangements. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that adopting ASU 2016-02 will have on its financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. This standard update provides guidance for balance sheet classification of deferred taxes. This standard requires that deferred tax assets and liabilities be classified as non-current on the balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount on the balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual period. The Company is currently evaluating the impact that adopting ASU 2015-17 will have on its financial statements.

Note K –ACCOUNTING POLICIES

Patents

Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of September 30, 2016, the Company does not believe there has been any impairment of its patents.

Stock-based Compensation

Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.

Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model. Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates.

Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule.

Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility.

Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.

HEALTH DISCOVERY CORPORATION

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Corporate Overview

Our Company is a pattern recognition company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery. The terms artificial intelligence and machine learning are sometimes used to describe pattern recognition tools.

HDC’s mission is to use its patents, intellectual prowess, and clinical partnerships principally to identify patterns that can advance the science of medicine, as well as to advance the effective use of our technology in other diverse business disciplines, including the high-tech, financial, and healthcare technology markets.

Our historical foundation lies in the molecular diagnostics field where we have made a number of discoveries that play a role in developing more personalized approaches to the diagnosis and treatment of certain diseases. However, our Support Vector Machine (“SVM”) assets in particular have broad applicability in many other fields. Intelligently applied, HDC’s pattern recognition technology can be a portal between enormous amounts of otherwise undecipherable data and truly meaningful discovery.

Our Company’s principal asset is its intellectual property which includes advanced mathematical algorithms called SVM and Fractal Genomic Modeling (FGM), as well as biomarkers that we discovered by applying our SVM and FGM techniques to complex genetic and proteomic data. Biomarkers are biological indicators or genetic expression signatures of certain disease states. Our intellectual property is protected by over 60 patents that have been issued or are currently pending around the world.

Our business model has evolved over time to respond to business trends that intersect with our technological expertise and our capacity to professionally manage these opportunities. In the beginning, we sought only to use our SVMs internally in order to discover and license our biomarker signatures to various diagnostic and pharmaceutical companies. Today, our commercialization efforts include: utilization of our discoveries and knowledge to help develop diagnostic and prognostic predictive tests; licensing of the SVM and FGM technologies directly to diagnostic companies; and the potential formation of new ventures with domain experts in other fields where our pattern recognition technology holds commercial promise.

Operational Activities

The Company markets its technology and related developmental expertise to prospects in the healthcare, biotech, and life sciences industries. Given the scope of some of these prospects, the sales cycle can be quite long, but management believes that these marketing efforts may produce favorable results in the future.

NeoGenomics License

On January 6, 2012, we entered into a Master License Agreement (the “NeoGenomics License”) with NeoGenomics Laboratories, Inc. (“NeoGenomics Laboratories”), a wholly owned subsidiary of NeoGenomics, Inc. (“NeoGenomics”). Pursuant to the terms of the NeoGenomics License, we granted to NeoGenomics Laboratories and its affiliates an exclusive worldwide license to certain of our patents and know-how to use, develop and sell products in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any “Laboratory Developed Tests” or LDTs or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer. We retain all rights to in-vitro diagnostic (IVD) test kit development.

Upon execution of the NeoGenomics License, NeoGenomics paid us $1,000,000 in cash and issued to us 1,360,000 shares of NeoGenomic’s common stock, par value $0.001 per share, which had a market value of $1,945,000 using the closing price of $1.43 per share for NeoGenomic’s common stock on January 6, 2012. In addition, the NeoGenomics License provides for milestone payments in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the NeoGenomics License. Milestone payments will be in increments of $500,000 for every $2,000,000 in GAAP revenue recognized by NeoGenomics up to a total of $5,000,000 in potential milestone payments. After $20,000,000 in cumulative GAAP revenue has been recognized by NeoGenomics, we will receive a royalty of (i) 6.5% (subject to adjustment under certain circumstances) on net revenue generated from all Licensed Uses except for the Cytogenetic Interpretation System and the Flow Cytometry Interpretation System and (ii) a royalty of 50% of net revenue (after the recoupment of certain development and commercialization costs) that NeoGenomics derives from any sublicensing arrangements it may put in place for the Cytogenetic Interpretation System and the Flow Cytometry Interpretation System.

HEALTH DISCOVERY CORPORATION

Management’s Discussion and Analysis, continued

NeoGenomics agreed to use its best efforts to commercialize certain products within one year of the date of the license, subject to two one-year extensions per product if needed, including a “Plasma Prostate Cancer Test”, a “Pancreatic Cancer Test”, a “Colon Cancer Test”, a “Cytogenetic Interpretation System”, and a “Flow Cytometry Interpretation System.” NeoGenomics has completed both of its one-year extension terms of the license.

If NeoGenomics has not generated $5.0 million of net revenue from products, services and sublicensing arrangements by January 2017, we may, at our option, revoke the exclusivity with respect to any one or more of the initial licensed products, subject to certain conditions. The Company does not expect NeoGenomics to generate $5.0 million of net revenue related from products, services and sublicensing arrangements by January 2017.

The Company is evaluating its rights under the license agreement and the best possibility to commercialize the Company’s technologies.

Plasma Test for Prostate Cancer

NeoGenomics is developing a Blood Test for Prostate Cancer under the direction of Dr. Maher Albitar using the genes patented by HDC. The test is performed on blood plasma and urine rather than only prostate tissue biopsies. NeoGenomics completed Phase I of their research and published the results in 2014. Additionally, NeoGenomics completed Phase II of their prostate test validation in 2014. The results were largely the same as those published regarding Phase I. NeoGenomics continues working on this test, named NeoLAB™ Prostate – Liquid Alternative to Biopsy. Per the license agreement, any commercial use of the NeoLAB™ Prostate Test by NeoGenomics will require compensation to HDC.

Cytogenetic Analysis

Cytogenetic analysis is the science of studying chromosomes. Microscopic evaluation of individual chromosomes remains the first step in the evaluation of the human genome. Cytogenetic analysis is performed on almost all patients with hematopoietic diseases (blood cancers such as leukemia and lymphoma) and on a significant number of patients with solid tumors. The collected data is useful for diagnosis, prognosis and monitoring of diseases. Currently, specially trained technicians perform most of the analysis manually. The work is labor-intensive and subjective. Computer automation of this work could significantly reduce cost and improve the quality of the test. The Company has spent a considerable amount of time using SVM Technology to create significant improvement in cytogenetic analysis.

Flow Cytometry

Management believes that our efforts to develop an SVM-based diagnostic test to help interpret flow cell cytometry data for myelodysplastic syndrome (pre-leukemia) has resulted in a successful proof of concept. The Company is now capable of completing development, final validation and commercialization of the new diagnostic test for the interpretation of flow cytometry data.

SVM Capital, LLC

In January 2007, SVM Capital, LLC (“SVM Capital”) was formed as a joint venture between HDC and Atlantic Alpha Strategies, LLC (“Atlantic Alpha”) to explore and exploit the potential applicability of our SVM technology to quantitative investment management techniques. Atlantic Alpha’s management has over thirty years of experience in commodity and futures trading.

HEALTH DISCOVERY CORPORATION

Management’s Discussion and Analysis, continued

On June 16, 2015, SVM Capital joined Manifold Partners, LLC (“Manifold Partners”) as a partner. Manifold Partners is a San Francisco-based multi-strategy portfolio management firm specializing in quantitative investment methodologies. As a part of the partnership, SVM Capital will contribute their proprietary service to the collaboration with Manifold Partners. This new collaboration will be known as Manifold Vector. SVM Capital specializes in the application of an artificial intelligence technique to investment strategies. SVM Capital has developed mathematical algorithms to rank-order S&P 500 stocks to determine investment desirability, including long and short equity positions. Importantly, only fundamental corporate data is analyzed, which Manifold Partners believes to be unique in the quantitative investment field. This technology is an outgrowth of the machine learning techniques created by the Company.

Intellectual Property Developments

In January 2016, the U.S. Patent Office issued a notice of allowance of the Company’s application covering analysis of chromosomal abnormalities using support vector machines. The automated analysis method greatly reduces the time required for visual inspection of images of chromosomes while providing more accurate and repeatable results. The Company has a companion application covering this technology still pending in Europe.

The Company now holds the exclusive rights to 53 issued U.S. and foreign patents covering uses of SVM and FGM technology for discovery of knowledge from large data sets. The Company also has 8 pending U.S. and foreign patent applications covering uses of the SVM technology as well as diagnostic methods that have been discovered using the SVM technology. A reduction in the total number of issued and pending patents during 2015 resulted from the Company’s decision to allow certain foreign patents issued and/or filed in countries that were deemed to have lower strategic value to lapse. In addition, a few U.S. patents that were either near the ends of their terms and/or had parallel applications with broader claims in force were allowed to expire. In addition, significant changes in the U.S. Patent Laws relating to the eligibility of certain subject matter for patent protection influenced the Company’s decision to abandon a few of its pending U.S. applications. This in turn reduced the Company’s total expenses for patent maintenance.

Intel Update

As previously disclosed, the Company submitted a patent application to provoke an interference with Intel’s Patent No. 7,685,077. The application file had been transferred to the U.S. Patent Office’s Interference Division.

On September 21, 2016, the Company received notification that the United States Patent and Trademark Office (“USPTO”) declared an Interference between the Company’s pending patent application covering SVM-Recursive Feature Elimination (“SVM-RFE”) and Intel’s Patent No. 7,685,077, entitled “Recursive Feature Eliminating Method based on a Support Vector Machine”. An Interference is an administrative proceeding within the USPTO that is used to determine which party was the first to invent an invention that is claimed in two (or more) independently-owned patent applications. The Company has been designated the “Senior Party” in the Interference, meaning that it is entitled to a presumption of prior inventorship based on its earlier filing date. As the “Junior Party”, the burden falls upon Intel to prove that it conceived and reduced the claimed invention to practice prior to the Company’s earlier filing date.

In addition to the patent application involved in the Interference, the Company currently has three issued U.S. patents and five issued foreign patents covering the SVM-RFE method.

HEALTH DISCOVERY CORPORATION

Management’s Discussion and Analysis, continued

Three Months Ended September 30, 2016 Compared with Three Months Ended September 30, 2015

Revenue

For the three months ended September 30, 2016, revenue was $10,847 compared with $12,050 for the three months ended September 30, 2015. The revenue earned during the third quarter in 2016 and 2015 is related to the revenue recognition of the Vermillion settlement.

Operating and Other Expenses

Amortization expense was $65,680 for the three months ended September 30, 2016 and $65,875 for the three months ended September 30, 2015. Amortization expense relates primarily to the costs associated with filing patent applications and acquiring rights to the patents.

Professional and consulting fees totaled $51,848 for the three months ended September 30, 2016, compared with $30,965 for the same 2015 period. These fees consist primarily of patent filing and maintenance costs, professional fees, and accounting fees. The increase was due to higher patent filing fees.

Legal fees decreased over the three-month period with fees totaling $6,225 during the three months ended September 30, 2016 and $9,000 during the same period in 2015.

Research and development expense was $9,000 for both the three months ended September 30, 2016 and 2015. This expense for research and development relates primarily to work completed under the NeoGenomics License.

Compensation expense of $56,179 for the three months ended September 30, 2016 was higher than the $48,328 reported for the comparable 2015 period. The increase is attributed to the cost associated with option grants to employees.

Other general and administrative expense increased to $42,514 for the three months ended September 30, 2016, compared to $33,438 for the same period in 2015. This increase was related to expenses associated with directors’ options.

Other Income and Expense

The Company received a portion of the NeoGenomics license fee in NeoGenomics stock. The Company has chosen to measure the gain or loss on the value of this asset using the fair value option method. During the three month period ended September 30, 2016, the NeoGenomics stock fair value increased by $3,240, which is recorded as other income in the statements of operations. During the same three month period in 2015, the NeoGenomics stock fair value increased by $9,275.

As previously discussed in Note H to the financial statements, the Company negotiated a reduction of amounts owed with certain service providers. As a result, the Company realized an increase in other income and expense (forgiveness on payables) of $121,503 during the three month period ended September 30, 2015.

Nine Months Ended September 30, 2016 Compared with Nine Months Ended September 30, 2015

Revenue

For the nine months ended September 30, 2016, revenue was $32,665 compared with $33,754 for the nine months ended September 30, 2015. The revenue earned is almost entirely related to the licensing revenue recognition for the Vermillion settlement.

Operating and Other Expenses

Amortization expense was $197,234 for the nine months ended September 30, 2016 and $197,770 for the nine months ended September 30, 2015. Amortization expense relates primarily to the costs associated with filing patent applications and acquiring rights to the patents.

HEALTH DISCOVERY CORPORATION

Management’s Discussion and Analysis, continued

Professional and consulting fees were $173,274 for the nine months ended September 30, 2016 compared with $129,377 for the same 2015 period. The increase was due to higher patent filing fees.

Legal fees totaled $21,225 during the nine months ended September 30, 2016 compared to $37,357 during the same period in 2015. The reduction was due to settling the FTC Matter in 2015 that did not reoccur in 2016.

Research and development fees were $27,000 for the nine months ended September 30, 2016 and $31,813 for the same period in 2015. This expense for research and development relates primarily to work completed under the NeoGenomics License.

Compensation expense of $233,035 for the nine months ended September 30, 2016 was more than the $142,665 reported for the comparable 2015 period. The increase is attributed to the cost associate with option grants to employees during the second quarter of 2016.

Other general and administrative expenses decreased to $147,811 for the nine months ended September 30, 2016 compared to $116,112 in 2015. This increase was related to expenses associated with directors’ options granted in the second quarter of 2016.

Other Income and Expense

The Company received a portion of the NeoGenomics license fee in NeoGenomics stock. The Company has chosen to measure the gain or loss on the value of this asset using the fair value option method. During the nine month period ended September 30, 2016, the NeoGenomics stock fair value increased by $6,096, which is recorded as other income in the statements of operations. During the same period in 2015, the NeoGenomics stock increased by $72,231.

Because the Company had issued warrants exceeding the amount of common shares available if holders exercised all of the previously issued outstanding options and warrants, the Company recorded an increase in the common stock warrants liability of $1,196,612 during the first and second quarters of 2016.

As a result of the settlement with the FTC over actions by previous management, the Company recognized a settlement expense of $17,693 during the first quarter 2015.

Liquidity and Capital Resources

We have prepared our financial statements on a “going concern” basis, which presumes that we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future.

Our ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing and successfully bringing our technologies to the market. The outcome of these matters cannot be predicted at this time. Our financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should we be unable to continue in business.

Additionally, the Company is attempting to encourage the Series C Preferred Stockholders to exercise some or all of their warrants in order to help fund the operations of the Company.

At September 30, 2016, the Company had $183,451 in cash and total current liabilities of $390,191. The primary amount of current liabilities relates to $206,637 in dividends payable and $140,166 in accounts payable. Additionally, we continue to sell our NeoGenomics Stock in order to fund operations. Although the NeoGenomics stock has increased in value since the initial acquisition date, the number of shares and amount of cash we can generate from the sale of NeoGenomics Stock is subject to fluctuating market and price conditions. As a result, we will not have sufficient resources to meet all of our current obligations unless the Company is able to secure funds via licensing activity or other forms of fund raising either in the debt or equity markets. During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. During the three month period ended March 31, 2016, the Company sold 3,000,000 of these shares and received $90,000 in proceeds. None of these options are definitive and there is no guarantee the Company will be successful in these fund raising efforts. The Company estimates cash will be depleted by the end of first quarter 2017 unless the Company is able to raise additional capital or amend the agreement with NeoGenomics.

HEALTH DISCOVERY CORPORATION

Management’s Discussion and Analysis, continued

At September 30, 2016, the Company had no contractual obligations that require disclosure.

The Company has relied primarily on equity and debt financing for liquidity. The Company produced sales, licensing, and developmental revenue starting in late 2005 and must increase revenues in order to generate sufficient cash to continue operations. The Company’s plan to have sufficient cash to support operations is comprised of selling its NeoGenomics Stock, generating revenue through licensing its patent portfolio, providing services related to those patents, and obtaining additional equity or debt financing. Since January 2015, the Company has been unable to generate significant revenue, as further described above. As a result, the Company has implemented a cash conservation program.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that provide financing, liquidity, market or credit risk support or involve leasing, hedging or research and development services for our business or other similar arrangements that may expose us to liability that is not expressly reflected in the financial statements.

Forward-Looking Statements

This Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 12E of the Securities Exchange Act of 1934, including or related to our future results, certain projections and business trends. Assumptions relating to forward-looking statements involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. When used in this Report, the words “estimate,” “project,” “intend,” “believe,” “expect” and similar expressions are intended to identify forward-looking statements. Although we believe that assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate, and we may not realize the results contemplated by the forward-looking statement. Management decisions are subjective in many respects and susceptible to interpretations and periodic revisions based on actual experience and business developments, the impact of which may cause us to alter our business strategy or capital expenditure plans that may, in turn, affect our results of operations. In light of the significant uncertainties inherent in the forward-looking information included in this Report, you should not regard the inclusion of such information as our representation that we will achieve any strategy, objective or other plans. The forward-looking statements contained in this Report speak only as of the date of this Report as stated on the front cover, and we have no obligation to update publicly or revise any of these forward-looking statements. These and other statements which are not historical facts are based largely on management’s current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by such forward-looking statements. These risks and uncertainties include, among others, the failure to successfully develop a profitable business, delays in identifying customers, and the inability to retain a significant number of customers, as well as the risks and uncertainties described in “Risk Factors” section to our Annual Report for the fiscal year ended December 31, 2015.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not Applicable.

Item 4. Controls and Procedures

As of the end of the period covered by this report (the “Evaluation Date”), we carried out an evaluation regarding the fiscal quarter ended September 30, 2016, under the supervision and with the participation of our management, including our Chief Executive Officer, who is also serving as our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon this evaluation, our management concluded that, as of the Evaluation Date, because of the Company’s internal control weakness, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed in the reports that are filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms and that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management including our Chief Executive Officer, as appropriate, to allow timely decisions regarding required disclosure.

HEALTH DISCOVERY CORPORATION

Our Annual Report on Form 10-K contains information regarding a material weakness in our internal control over financial reporting as of December 31, 2015 due to an inadequate segregation of duties resulting from our small number of employees.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that the Company’s disclosure controls and procedures will detect or uncover every situation involving the failure of persons within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports.

The Company’s management is also responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. As of the Evaluation Date, no changes in the Company’s internal control over financial reporting occurred that have materially affected or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2015, the Company had issued a total of 30,000,000 preferred shares. The Series C Preferred Shares were fully subscribed in the third quarter 2015. The Company received total net proceeds of $900,000, of which $568,000 was received in the period ended September 30, 2015. The Series C Preferred Shares were accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire. The warrants were valued at $0.0219 each using the Black Scholes Method.

The Series C Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. If the Company were to be dissolved, the Series C Preferred Stock receives preferential treatment over Common Stock.

HEALTH DISCOVERY CORPORATION

Item 3. Defaults upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following exhibits are attached hereto or incorporated by reference herein (numbered to correspond to Item 601(a) of Regulation S-K, as promulgated by the Securities and Exchange Commission) and are filed as part of this Form 10-Q:

31.1

Rule 13a-14(a)/15(d)-14(a) Certifications of Chief Executive Officer and Principal Financial Officer. Filed herewith.

32.1

Section 1350 Certifications of Chief Executive Officer and Principal Financial Officer. Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Health Discovery Corporation
	Registrant

Date: November 21, 2016	By:	/s/ Kevin Kowbel
	Printed Name: Kevin Kowbel
	Title: Chief Executive Officer, Principal Financial Officer, and Principal Accounting Officer

EX-31.1 2 t1600733_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin Kowbel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Health Discovery Corporation (the “Registrant”);

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. As the Registrant’s sole certifying officer. I am responsible for establishing and maintaining disclosure control and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the Registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: November 21, 2016	/s/ Kevin Kowbel
	Kevin Kowbel
	Chief Executive Officer, Principal Financial Officer and
	Principal Accounting Officer

EX-32.1 3 t1600733_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report on Form 10-Q for the period ended September 30, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 21, 2016

	/s/ Kevin Kowbel.
	Kevin Kowbel
	Chief Executive Officer, Principal Financial Officer, and Principal Accounting Officer

EX-101.INS 4 hdvy-20160930.xml XBRL INSTANCE DOCUMENT 0001141788 2014-12-31 0001141788 2015-07-01 2015-09-30 0001141788 hdvy:StockOptionsAndWarrantsMember hdvy:EmployeesDirectorsAndConsultantsMember 2015-07-01 2015-09-30 0001141788 2015-01-01 2015-09-30 0001141788 hdvy:StockOptionsAndWarrantsMember hdvy:EmployeesDirectorsAndConsultantsMember 2015-01-01 2015-09-30 0001141788 2015-01-01 2015-12-31 0001141788 us-gaap:SeriesCPreferredStockMember 2015-01-01 2015-12-31 0001141788 2015-12-31 0001141788 us-gaap:SeriesCPreferredStockMember 2015-12-31 0001141788 hdvy:StockOptionsAndWarrantsMember 2016-02-08 0001141788 hdvy:StockOptionsAndWarrantsMember 2016-02-01 2016-02-08 0001141788 us-gaap:VicePresidentMember hdvy:StockOptionsAndWarrantsMember 2016-02-01 2016-02-08 0001141788 us-gaap:ExecutiveVicePresidentMember hdvy:StockOptionsAndWarrantsMember 2016-02-01 2016-02-08 0001141788 hdvy:EmployeesAndConsultantsMember hdvy:StockOptionsAndWarrantsMember 2016-02-01 2016-02-08 0001141788 us-gaap:DirectorMember us-gaap:PrivatePlacementMember 2016-01-01 2016-03-31 0001141788 2016-03-31 0001141788 us-gaap:DirectorMember 2016-05-17 0001141788 us-gaap:BoardOfDirectorsChairmanMember 2016-05-17 0001141788 us-gaap:DirectorMember 2016-05-01 2016-05-17 0001141788 us-gaap:BoardOfDirectorsChairmanMember 2016-05-01 2016-05-17 0001141788 us-gaap:ChiefExecutiveOfficerMember 2016-05-01 2016-05-17 0001141788 hdvy:HenryKaplanMember 2016-05-01 2016-05-17 0001141788 hdvy:GeorgeMcgovernMember 2016-05-01 2016-05-17 0001141788 hdvy:WilliamQuirkMember 2016-05-01 2016-05-17 0001141788 2016-06-30 0001141788 2016-07-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsMember hdvy:EmployeesDirectorsAndConsultantsMember 2016-07-01 2016-09-30 0001141788 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsMember hdvy:EmployeesDirectorsAndConsultantsMember 2016-01-01 2016-09-30 0001141788 us-gaap:DirectorMember us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001141788 us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsMember 2016-01-01 2016-09-30 0001141788 us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001141788 us-gaap:OtherExpenseMember hdvy:NeoGenomicsLaboratoriesIncMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroTwoSevenMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroThreeSixMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroFourZeroMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroFiveZeroMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroThreeZeroMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroSixtyMember 2016-01-01 2016-09-30 0001141788 us-gaap:PatentsMember 2016-01-01 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroThreeFiveMember 2016-01-01 2016-09-30 0001141788 2016-09-30 0001141788 us-gaap:SeriesCPreferredStockMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsMember 2016-09-30 0001141788 us-gaap:PrivatePlacementMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroTwoSevenMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroThreeSixMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroFourZeroMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroFiveZeroMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroThreeZeroMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroSixtyMember 2016-09-30 0001141788 hdvy:StockOptionsAndWarrantsAwardsMember hdvy:DollarZeroPointZeroThreeFiveMember 2016-09-30 0001141788 us-gaap:CarryingReportedAmountFairValueDisclosureMember hdvy:NeoGenomicsLaboratoriesIncMember 2016-09-30 0001141788 us-gaap:EstimateOfFairValueFairValueDisclosureMember hdvy:NeoGenomicsLaboratoriesIncMember 2016-09-30 0001141788 2015-09-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure iso4217:USDhdvy:Warrant HEALTH DISCOVERY CORP 0001141788 hdvy --12-31 Smaller Reporting Company 10-Q 2016-09-30 false 2016 Q3

7642

417208

183451

506551

141978

148074

559186

331525

195

941066

744026

1500447

1075551

37633

140166

206637

43388

339268

626926

390191

104853

72312

731779

462503

560732

900000

27410930

28873471

-27202994

-29160423

768668

613048

1500447

1075551

60690

60885

3044729

3241769

30000000

45000000

30000000

300000000

450000000

268718989

271718989

268718989

271718989

12050

33754

10847

32665

65680

197039

65680

197039

30965

129377

51848

173274

9000

37357

6225

21225

9000

31813

9000

27000

48328

142665

56179

233035

33438

116112

42514

147811

196606

655094

231446

799579

-184556

-621340

-220599

-766914

-17917

-160706

3240

6096

27192

232937

1196612

17693

130778

176041

3240

-1190516

-53778

-445299

-217359

-1957430

266052322

265163433

271718989

271052322

-0.0002

-0.0017

-0.0008

-0.0072

11512

102233

39700

73698

-160706

6096

197770

197234

-1969

-32541

-98639

102533

-520556

-323757

331465

120000

90000

688000

90000

498909

-233757

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Note D - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Stock-based compensation expense included in our net loss for the three months and nine months ended September 30, 2016 was $35,163 and $175,931, respectively, for stock options granted to employees, directors, and consultants. Stock-based compensation expense included in our net loss for the three months and nine months ended September 30, 2015 was $17,071 and $51,212, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2016, there was $192,993 of unrecognized cost related to stock option grants.  The cost is to be recognized over the remaining vesting periods that average approximately 2.25 years.  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In connection with their election to the Board of Directors, on May 17, 2016, the Company granted to Mr. Henry Kaplan, Mr. Kevin Kowbel, Mr. George McGovern, and Mr. William Quirk each an option to purchase 1,500,000 shares of the Company’s common stock. The options for Messrs. Kaplan, Kowbel, McGovern and Quirk vest 250,000 shares every six months, have an exercise price of $0.035, and expire on May 17, 2026. The fair value of each option granted is $0.0265 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.89%, an expected life of 5 years, and volatility of 102%. The aggregate computed fair value of these options is $158,756, and this amount will be charged as an expense over the three-year vesting period. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Additionally, in recognition of his leadership as Chairman of the Board of Directors and CEO, on May 17, 2016, the Company granted to Mr. Kevin Kowbel an option to purchase 3,000,000 shares of the Company’s common stock. The options for Mr. Kowbel vest immediately, have an exercise price of $0.035, and expire on May 17, 2026. The fair value of each option granted is $0.0265 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.89%, an expected life of 5 years, and volatility of 102%. The aggregate computed fair value of these options is $79,519, and this amount was charged as an expense during the second quarter of 2016. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">On February 8, 2016, the Company granted options to purchase 5,000,000 shares of the Company’s common stock to a group of employees and consultants in recognition of their efforts to lower the Company’s monthly expenditures and compensation and their continuing contributions to the Company. The options vest over a two-year period, have an exercise price of $.03, and expire on February 8, 2026. Within the group of 5,000,000 options, the Company’s Vice President, Mark A. Moore, Ph.D., received an option to purchase 500,000 shares of the Company’s common stock and the Company’s Senior Vice President, Hong Zhang, Ph.D., received an option to purchase 1,250,000 shares of the Company’s common stock. The fair value of each option granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.99%, an expected life of 5 years, and volatility of 96%. The aggregate computed fair value of these options is $109,271, and this amount will be charged as an expense over the two-year vesting period. Because at the time of issuance, these options exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company needed to increase the authorized shares of common stock in order to satisfy these options. The shareholders of the Company approved this increase in authorized shares on May 17, 2016. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2015, the Company had issued a total of 30,000,000 preferred shares. The Series C Preferred Shares were fully subscribed in the third quarter 2015. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were issued during the three months ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. Because at the time of issuance, these warrants exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company needed to increase the authorized shares of common stock in order to satisfy these options. The shareholders of the Company approved this increase in authorized shares on May 17, 2016. The fair value of each warrant granted was $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of March 31, 2016, 7,000,000 shares of this offering were sold. During the three and six month periods ended March 31, 2016, the Company sold 3,000,000 of these shares and received $90,000 in proceeds. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants were issued during the three months ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. Because at the time of issuance, these warrants exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company needed to increase the authorized shares of common stock in order to satisfy these options. The shareholders of the Company approved this increase in authorized shares on May 17, 2016. The fair value of each warrant granted was $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Furthermore, as a result of the Company issuing options and warrants which exceeded the amount of common shares available if the holders exercised the previously issued outstanding options and warrants, the Company recorded an increase in the common stock warrants liability during the first quarter of 2016 of $940,812 and $255,800 during the second quarter of 2016. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">As previously disclosed above, the Company had issued options and warrants which exceeded the amount of common shares available if the holders exercised all of the previously issued outstanding options and warrants. This created a common stock warrant liability for the Company. During the first quarter, based upon the trading price of the Company’s common stock, this liability increased by $940,812 and during the second quarter of 2016 increased by $1,196,612. At the Annual Shareholder Meeting of the Company held on May 17, 2016, the shareholders approved an increase to the authorized shares of common and preferred stock. As a result, the Company has enough common stock available if the holders exercised all of the previously issued outstanding options and warrants. This resulted in there no longer being a common stock warrant liability for the Company. With the reduction in the common stock warrant liability, the Company increased the common stock value within the balance sheet. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2016, there were 100,750,000 option and warrant shares outstanding with a weighted average exercise price of $0.033. The following schedule summarizes combined stock option and warrant information as of September 30, 2016: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr> <td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">Exercise Prices</td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number Outstanding</td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted- Average Remaining Contractual Life (years)</td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number Exercisable</td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Remaining Contractual Life (years) of Exercisable Options and Warrants</td> <td style="text-align: center; padding-bottom: 1.5px; font-weight: bold; vertical-align: bottom;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure;"> <td style="width: 314px; text-align: center;">$0.027</td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 267px; text-align: right;">3,000,000</td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 297px; text-align: center;">6.75</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 266px; text-align: right;">3,000,000</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 250px; text-align: center;">6.75</td> <td style="width: 3px; text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center;">$0.030</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">72,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">68,250,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center;">$0.035</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.75</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.75</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center;">$0.036</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">7,750,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">7.00</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,833,335</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">7.00</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center;">$0.040</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center;">$0.050</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center; padding-bottom: 1.5px;">$0.060</td> <td style="padding-bottom: 1.5px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">7,000,000</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 1.5px;"> </td> <td style="text-align: left; padding-bottom: 1.5px;"> </td> <td style="text-align: center; padding-bottom: 1.5px;">9.50</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 1.5px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">7,000,000</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 1.5px;"> </td> <td style="text-align: left; padding-bottom: 1.5px;"> </td> <td style="text-align: center; padding-bottom: 1.5px;">9.50</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center; padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">100,750,000</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;"> </td> <td style="text-align: left;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">90,083,335</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;"> </td> <td style="text-align: left;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The weighted average remaining life of all outstanding warrants and options at September 30, 2016 are 9.35 years. The aggregate intrinsic value of all options and warrants outstanding and exercisable as of September 30, 2016 was $392,400, based on the market closing price of $0.0351 on September 30, 2016, less exercise prices.

<div> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Note F – STOCKHOLDERS’ EQUITY <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Series C Preferred Stock <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2015, the Company had issued a total of 30,000,000 preferred shares. The Series C Preferred Shares were fully subscribed in the third quarter of 2015. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire.  The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire.  The fair value of each warrant granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%. The aggregate fair value of these warrants is $656,380. <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies. <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Each share of Series C Preferred Stock may be converted into one share of Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. If the Company were to be dissolved, the Series C Preferred Stock receives preferential treatment over Common Stock. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of September 30, 2016, 7,000,000 shares of this offering have been sold. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire.  The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire.  The fair value of each warrant granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%.</div> </div>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Note H – COMMITMENTS AND CONTINGENCIES <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0in; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">On July 17, 2013, the Company received a Civil Investigative Demand (the "Demand") from the Federal Trade Commission of the United States of America (the "FTC") relating to the Company's MelApp software application. In the Demand, the FTC requested information relating to potentially unfair or deceptive acts or practices related to (i) false advertising and (ii) consumer privacy and data security, in violation of Trade Commission Act, 15 U.S.C. Sections 45 and 42. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">On February 23, 2015, the FTC notified the Company of its approval, by a vote of 4-1, to accept an Agreement Containing Consent Order (“Agreement”). This Agreement was for settlement purposes only. The Company neither admitted nor denied any of the allegations, except as specifically stated in the Agreement. The Company believed the effort to contest this matter with the FTC would require funds greater than the Company had at its disposal. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Agreement does, among other things, bar the Company from claiming that any device detects or diagnoses melanoma or its risk factors, or increases users’ chances of early detection, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. The Agreement also prohibits the Company from making any other misleading or unsubstantiated claims about a device’s health benefits or efficacy, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. Finally, the Company was required to pay $17,693 to the FTC, which was accrued during the three month period ended March 31, 2015. This amount is included as Settlement Expense in the accompanying statements of operations for the nine-month period ended September 30, 2015. <p style="margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s balance sheet for the year ended December 31, 2014 reflected an accrued liability of approximately $239,910 for professional services.  In an effort to conserve cash, the Company worked with several of the vendors regarding a portion of this amount by negotiating with the service providers regarding potential reduction of the amount billed. During the quarter ended September 30, 2015, the Company and the service providers negotiated the amounts owed and as a result, the Company recorded a decrease in accounts payables of $121,503. During the period ended September 30, 2016 there was no forgiveness on payables. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is subject to various claims primarily arising in the normal course of business.  Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

<div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Note K –ACCOUNTING POLICIES <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Patents <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued.  Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable.  The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of September 30, 2016, the Company does not believe there has been any impairment of its patents. <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Stock-based Compensation <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model.  Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule.   <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility. <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.</div> </div>

<div> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Stock-based Compensation <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model.  Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule.   <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility. <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.</div> </div>

<div> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 99%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom; font-weight: bold;" nowrap="nowrap">Exercise Prices</td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom; font-weight: bold;" colspan="2" nowrap="nowrap">Number Outstanding</td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted- Average Remaining Contractual Life (years)</td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom; font-weight: bold;" colspan="2" nowrap="nowrap">Number Exercisable</td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted Average Remaining Contractual Life (years) of Exercisable Options and Warrants</td> <td style="text-align: center; padding-bottom: 1px; vertical-align: bottom; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center; width: 314px;">$0.027</td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;"> </td> <td style="text-align: right; width: 267px;">3,000,000</td> <td style="text-align: left; width: 16px;"> </td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;"> </td> <td style="text-align: center; width: 297px;">6.75</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 266px;">3,000,000</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: center; width: 250px;">6.75</td> <td style="text-align: left; width: 3px;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center;">$0.030</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">72,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">68,250,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center;">$0.035</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.75</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">9.75</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center;">$0.036</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">7,750,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">7.00</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,833,335</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">7.00</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center;">$0.040</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center;">$0.050</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">1.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure;"> <td style="text-align: center; padding-bottom: 1px;">$0.060</td> <td style="padding-bottom: 1px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">7,000,000</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 1px;"> </td> <td style="text-align: left; padding-bottom: 1px;"> </td> <td style="text-align: center; padding-bottom: 1px;">9.50</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 1px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">7,000,000</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 1px;"> </td> <td style="text-align: left; padding-bottom: 1px;"> </td> <td style="text-align: center; padding-bottom: 1px;">9.50</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white;"> <td style="text-align: center; padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">100,750,000</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;"> </td> <td style="text-align: left;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">90,083,335</td> <td style="text-align: left;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;"> </td> <td style="text-align: left;"> </td> </tr> </table> </div>

115700

0.027 0.036 0.040 0.050 0.030 0.060 0.035 100750000 3000000 7750000 1000000 1000000 72000000 7000000 9000000 P9Y4M6D P6Y9M P7Y P1Y3M P1Y3M P9Y3M P9Y6M P9Y9M 90083335 3000000 6833335 1000000 1000000 68250000 7000000 3000000 P6Y9M P7Y P1Y3M P1Y3M P9Y3M P9Y6M P9Y9M

17071

51212

35163

175931

192993

P2Y

P3Y

P2Y3M

500000

1250000

5000000

3000000

1500000

250000

0.03

0.035

2026-02-08 2026-05-17 2026-05-17

0.0219

0.0265

0.0219

Black-Scholes pricing model

0.00

0.0000

0.00

0.0199

0.0189

0.0167

P5Y

0.96

1.02

0.9600

0.96

109271

158756

79519

656380

940812

255800

0.03 0.03 0.03 0.06 7000000 7000000

3000000

90000

100750000

0.20

0.033

0.20

392400 0.0351 0.03 0.03 0.03 0.06 The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days. 0.5000 P30D P30D 0.5000 0.5000 0.30 0.30 P30D P30D

0.0219

Black Scholes Method

1945000

148074

6096

18000 18000

Straight-line method

P17Y

262720

152906

239910

-121503

-53778

-445299

-217359

-1957430

65875

197770

65680

197234

-121503 -121503

1294

568000

0001141788us-gaap:PrivatePlacementMemberus-gaap:DirectorMember2015-09-30

7000000

0001141788hdvy:StockOptionsAndWarrantsMember2016-01-012016-03-31

940812

0001141788hdvy:StockOptionsAndWarrantsMember2016-01-012016-06-30

1196612

00011417882016-11-21 271718989 EX-101.SCH 5 hdvy-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Balance Sheets (unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations (unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Cash Flows (unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - REVENUE RECOGNITION link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - PATENTS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - INVESTMENT IN AVAILABLE FOR SALE SECURITIES link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - FINANCIAL CONDITION AND GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - REVENUE RECOGNITION (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - PATENTS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - STOCKHOLDERS' EQUITY (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - ACCOUNTING POLICIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 hdvy-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 hdvy-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 hdvy-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series C Preferred Stock [Member] Series C Preferred Stock Series C Preferred Stock Convertible Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current Assets Cash Cash Cash Cash, at Beginning of Period Cash, at End of Period Investment In Available For Sale Securities (Note G) Investment in NeoGenomics Stock available for sale Investment in Available For Sale Securities (Note G) Assets, Current Total Current Assets Total Current Assets Property, Plant and Equipment, Net Equipment, Less Accumulated Depreciation of $60,885 and $60,690 as of September 30, 2016 and December 31, 2015, respectively Equipment, Less Accumulated Depreciation of $39,555 and $37,061 Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent [Abstract] Other Assets Patents and patent related costs, net Aggregate of patents and patent related costs Patents, Less Accumulated Amortization of $3,241,769 and $3,044,729 as of September 30, 2016 and December 31, 2015, respectively Patents, Net of Amortization Assets Total Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current Liabilities Accounts Payable, Trade, Current Accounts Payable - Trade Accounts Payable, Current, Total Dividends Payable, Current Dividends Payable Dividend accrued on Series B preferred stock Deferred Revenue, Current Unearned revenue, current Deferred Revenue Deferred Revenue, Current, Total Common Stock Warrants Liability Common Stock Warrants Liability (Note D) It represent amount of common stock warrants liability. Liabilities, Current Current liabilities Total Current Liabilities Total Current Liabilities Liabilities, Noncurrent [Abstract] Long Term Liabilities Unearned revenue, long term Deferred Revenue Deferred Revenue Deferred Revenue, Noncurrent, Total Liabilities Total Liabilities Total Liabilities Stockholders Equity Attributable To Parent [Abstract] Stockholders' Equity Preferred Stock, Value, Issued Series C Preferred Stock, Convertible, 45,000,000 Shares Authorized; 30,000,000 Issued and Outstanding September 30, 2016 and December 31, 2015 Value of preferred shares issued Total Series C Preferred Stock Common Stocks, Including Additional Paid in Capital Common Stock, No Par Value, 450,000,000 Shares Authorized; 271,718,989 Shares Issued and Outstanding September 30, 2016; 268,718,989 Shares Issued and Outstanding December 31, 2015 Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated Deficit Accumulated Deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Stockholders' Equity Attributable To Parent Total Stockholders' Equity Total Stockholders' Equity Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity Total Liabilities and Stockholders' Equity Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation on equipment (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated amortization of patents Accumulated amortization Accumulated amortization on patents (in dollars) Accumulated Amortization Preferred Stock, Shares Authorized Series B preferred stock, shares authorized (in shares) Preferred stock, shares authorized Series B Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, No Par Value Common stock, no par value (in dollars per share) Common Stock, Shares Authorized Number of authorized shares of common stock Common stock, shares authorized Common Stock, Shares, Issued Number of shares sold during third and fourth quarters of 2012 Common stock, shares issued Number of shares sold during the period Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Income Statement [Abstract] Income Statement [Abstract] Revenues [Abstract] Revenues: License and Maintenance Revenue Licensing and Development Licensing and Development Operating Expenses [Abstract] Operating Expenses: Depreciation, Depletion and Amortization, Nonproduction Depreciation and Amortization Professional Fees Professional and Consulting Fees Legal Fees Legal Fees Research and Development Expense Research and development costs Research and Development Fees Research & Development Fees Labor and Related Expense Compensation Compensation Other General and Administrative Expense Other General and Administrative Expenses Operating Expenses Total Operating Expenses Total Operating Expenses Operating Income (Loss) Loss From Operations Loss From Operations Nonoperating Income (Expense) [Abstract] Other Income (Expense) Unrealized Gain (Loss) on Securities Unrealized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J) Unrealized Gain (Loss) on Available for Sale Securities (Note G) Unrealized Loss on Available for Sale Securities (Note G) Realized gain on sale of available for sale securities Realized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J) Realized Gain on Available for Sale Securities (Note G) Acquisition price for remaining shares Realized Gain on Sale of Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G) Realized Gain on Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G) Fair Value Adjustment of Warrants Increase in Warrants Liability (Note D) Other Expense - Change in Warrants Liability (Note D) Forgiveness On Payables Forgiveness on Payables Forgiveness on Accounts Payable - Trade Represents amount related to Forgiveness on Payables. Forgiveness on Payables (Note H) Litigation Settlement, Expense Settlement expense Settlement Expense Nonoperating Income (Expense) Total Other Income (Expense) Other Income (Expense), net Net Income (Loss) Attributable To Parent Net Loss Net Loss Net Income (Loss) Available to Common Stockholders, Basic Net Loss Attributable to Common Stockholders Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted Average Outstanding Shares - basic and diluted (in shares) Basic weighted average common shares outstanding Earnings Per Share, Basic and Diluted, Total Net Loss Per Share - basic and diluted (in dollars per share) Basic earnings per common share Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash Flows From Operating Activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: Share-Based Compensation Director option expenses Stock-based Compensation for Employees Stock-based Compensation Issuance of Stock and Warrants for Services or Claims Stock-based Compensation for Directors and Consultants Available-For-Sale Securities, Transfers To Trading, Gains (Losses), Excluding Other Than Temporary Impairments Unrealized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J) Unrealized Gain on Available for Sale Securities (Note J) Unrealized (Gain) Loss on Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G) Depreciation, Depletion and Amortization Depreciation and Amortization Depreciation and Amortization Increase (Decrease) In Accounts Receivable Decrease (Increase) in Accounts Receivable Decrease in Accounts Receivable Increase (Decrease) In Deferred Revenue Decrease in Deferred Revenue Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Accounts Payable - Trade Decrease in accounts payables Gain on Accounts Payable - Trade (Note H) Increase in Accounts Payable - Trade Increase (Decrease) in Trading Securities Increase in Available for Sale Securities Increase in Available for Sale Securities Net Cash Provided By (Used In) Operating Activities, Continuing Operations Net Cash Used by Operating Activities Net Cash Used in Operating Activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash Flows From Investing Activities: Proceeds From Sale Of Available-For-Sale Securities, Debt Proceeds from Sale of Available for Sale Securities (Note G) Net Cash Provided By (Used In) Investing Activities, Continuing Operations Net Cash (Used by) Provided by Investing Activities Net Cash Provided by Investing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows From Financing Activities: Proceeds from Common Stock Issuance Proceeds from Common Stock Issuance Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from Series C Preferred Stock Issuance Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Net (Decrease) Increase in Cash Net (Decrease) Increase in Cash Accounting Policies [Abstract] Accounting Policies [Abstract] Business Description and Basis of Presentation [Text Block] BASIS OF PRESENTATION Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Text Block] REVENUE RECOGNITION Earnings Per Share [Abstract] Earnings Per Share [Text Block] NET LOSS PER SHARE Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] PATENTS Stockholders Equity Note [Abstract] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Available-For-Sale Securities [Abstract] Available-for-sale Securities [Abstract] Investment In Available For Sale Securities [Text Block] INVESTMENT IN AVAILABLE FOR SALE SECURITIES The entire disclosure for investment in available for sale securities. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Financial Condition And Going Concern [Abstract] Financial Condition And Going Concern [Text Block] FINANCIAL CONDITION AND GOING CONCERN Represents disclosure about financial condition and going concern. New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] RECENT ACCOUNTING PRONOUNCEMENTS Significant Accounting Policies [Text Block] ACCOUNTING POLICIES Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Patents Compensation Related Costs, Policy [Policy Text Block] Stock-based Compensation New Accounting Pronouncements, Policy [Policy Text Block] RECENT ACCOUNTING PRONOUNCEMENTS Schedule Of Share Based Compensation Shares Authorized Under Stock Option And Warrants Outstanding By Exercise Price Range [Table Text Block] Schedule of stock option and warrants outstanding by exercise price range Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. Accrued Professional Fees Accrued professional liability Increase (Decrease) in Accounts Payable Increase (Decrease) in accounts payable Increase (Decrease) in accounts payable Deferred Revenue Total unearned revenue Schedule Of Share-Based Compensation Arrangements By Share-Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Award Type [Domain] Stock Options and Warrants Awards [Member] Warrants and Options Stock option and warrant Incremental common shares attributable to stock options that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented. A contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock and warrants at a predetermined price for a specified period of time. Share Based Compensation Shares Authorized Under Awards Stock Option and Warrants Plans By Exercise Price Range [Axis] Share Based Compensation Shares Authorized Under Awards Stock Option and Warrants Plans By Exercise Price Range [Axis] Information by type of estimate, including, but not limited to, upper and lower bound estimates and point estimates. Share Based Compensation Shares Authorized Under Awards Stock Option and Warrants Plans Exercise Price Range [Domain] Share Based Compensation Shares Authorized Under Awards Stock Option and Warrants Plans Exercise Price Range [Domain] Type of estimate, including, but not limited to, upper and lower bound estimates and point estimates. Dollar Zero Point Zero Two Seven [Member] Exercise Price $0.027 Represents the exercise price of $0.027 for stock options and warrants. Dollar Zero Point Zero Three Zero Member Exercise Price $0.030 Represents the exercise price of $0.030 for stock options and warrants. Dollar Zero Point Zero Three Five [Member] Exercise Price $0.035 Represents the exercise price of $0.035 for stock options and warrants. Dollar Zero Point Zero Three Six [Member] Exercise Price $0.036 Represents the exercise price of $0.036 for stock options and warrants. Dollar Zero Point Zero Four Zero [Member] Exercise Price $0.040 Represents the exercise price of $0.040 for stock options and warrants. Dollar Zero Point Zero Five Zero [Member] Exercise Price $0.050 Represents the exercise price of $0.050 for stock options and warrants. Dollar Zero Point Zero Sixty Member [Member] Exercise Price $0.060 Represents the exercise price of $0.060 for stock options and warrants. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Exercise Price Weighted average exercise price Exercise Prices Outstanding, December 31, 2014 Outstanding, September 30, 2015 The price at which the underlying security can be purchased -call option) or sold -put option). The exercise price is determined at the time the option and warrants contract is formed. Also known as the "strike price". Share Based Compensation Arrangement By Share Based Payment Award and Warrants Shares Outstanding Number outstanding Number Outstanding Outstanding, December 31, 2014 Outstanding, September 30, 2015 This number is shown on a company's balance sheet under the heading "Capital Stock" and is more important than the authorized shares or float. Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Outstanding Weighted Average Remaining Contractual Term 2 Weighted average remaining life of outstanding warrants and options Weighted-Average Remaining Contractual Life (years) Weighted average remaining contractual term for option awards and warrants outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Exercisable Number Number Exercisable The number of shares into which fully or partially vested stock options and warrants outstanding as of the balance sheet date can be currently converted under the option plan. Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Exercisable Weighted Average Remaining Contractual Term 1 Weighted Average Remaining Contractual Life (years) of Exercisable Warrants Weighted average remaining contractual term for vested portions of options and warrants outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Stock Options And Warrants [Member] Stock options and warrants Represents stock options and warrants. Title of Individual [Axis] Relationship to Entity [Domain] Employees, Directors, And Consultants [Member] Employees, directors, and consultants Information about parties. Employees And Consultants [Member] Employees and consultants Information about parties. Vice President [Member] Mark A. Moore, Ph.D. Executive Vice President [Member] Hong Zhang, Ph.D. Director [Member] Board of Directors Board of Directors Chairman [Member] Chairman of the Board of Directors and CEO Related Party [Axis] Related Party [Domain] Chief Executive Officer [Member] Mr. Kevin Kowbel Henry Kaplan [Member] Mr. Henry Kaplan Represents related party details. George Mcgovern [Member] Mr. George McGovern Represents related party details. William Quirk [Member] Mr. William Quirk Represents related party details. Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private placement Allocated Share-Based Compensation Expense Stock-based expense Stock-based compensation Net Increase Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized cost related to stock option grants Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Remaining vesting periods Number of option to purchase Number of option granted to purchase common stock Number of option to purchase Number of shares vested Number of shares vested Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price of option Option Expiration Date Option expiration date Represents option expiration date . Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Fair value of each option granted Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used Method used Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility rate Warrants and Rights Outstanding Aggregate computed value of warrants Derivative Liability Common stock warrant liability Stock Par Value Per Share For Warrants Shares warrant feature per share (in dollars per share) This element represents stock par value per share for warrant. Stock Par Value Per Share For Contingency Warrants Shares contingency warrant feature per share (in dollars per share) This element represents stock par value per share for contingency warrant. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of share authorized for issuance Stock Issued Under Private Placement Stock issued under private placement This element represents number of shares issued under the private placement. Number of shares sold Number of shares sold Proceeds from shares sold Proceeds from shares sold Option And Warrant Outstanding Option and warrant outstanding Number of options and warrants or rights outstanding. Weighted average exercise price Weighted average exercise price Price per share for exercise of warrants, condition one (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Exercisable Intrinsic Value Aggregate intrinsic value of outstanding and exercisable options and warrants outstanding and exercisable Represents the amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options and warrants outstanding and currently exercisable. Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Share Price Closing price of outstanding and exercisable options and warrants less exercise prices Represents the amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options and warrants outstanding and currently market closing price. Amortization charged on patents Amortization charged to operations Amortization Amortization of Intangible Assets, Total Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months Estimated amortization expense of patents at 2017 Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two Estimated amortization expense of patents at 2018 Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three Estimated amortization expense of patents at 2019 Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four Estimated amortization expense of patents at 2020 Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] EX-101.PRE 9 hdvy-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 21, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTH DISCOVERY CORP
Entity Central Index Key	0001141788
Trading Symbol	hdvy
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		271,718,989
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3

XML 11 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 183,451	$ 417,208
Investment in Available For Sale Securities (Note G)	148,074	141,978
Total Current Assets	331,525	559,186
Equipment, Less Accumulated Depreciation of $60,885 and $60,690 as of September 30, 2016 and December 31, 2015, respectively		195
Other Assets
Patents, Less Accumulated Amortization of $3,241,769 and $3,044,729 as of September 30, 2016 and December 31, 2015, respectively	744,026	941,066
Total Assets	1,075,551	1,500,447
Current Liabilities
Accounts Payable - Trade	140,166	37,633
Dividends Payable	206,637	206,637
Deferred Revenue	43,388	43,388
Common Stock Warrants Liability (Note D)		339,268
Total Current Liabilities	390,191	626,926
Long Term Liabilities
Deferred Revenue	72,312	104,853
Total Liabilities	462,503	731,779
Stockholders' Equity
Series C Preferred Stock, Convertible, 45,000,000 Shares Authorized; 30,000,000 Issued and Outstanding September 30, 2016 and December 31, 2015	900,000	560,732
Common Stock, No Par Value, 450,000,000 Shares Authorized; 271,718,989 Shares Issued and Outstanding September 30, 2016; 268,718,989 Shares Issued and Outstanding December 31, 2015	28,873,471	27,410,930
Accumulated Deficit	(29,160,423)	(27,202,994)
Total Stockholders' Equity	613,048	768,668
Total Liabilities and Stockholders' Equity	$ 1,075,551	$ 1,500,447

XML 12 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (unaudited) (Parentheticals) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accumulated depreciation on equipment (in dollars)	$ 60,885	$ 60,690
Accumulated amortization on patents (in dollars)	$ 3,241,769	$ 3,044,729
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	450,000,000	300,000,000
Common stock, shares issued	271,718,989	268,718,989
Common stock, shares outstanding	271,718,989	268,718,989
Series C Preferred Stock Convertible
Preferred stock, shares authorized	45,000,000	30,000,000
Preferred stock, shares issued	30,000,000	30,000,000
Preferred stock, shares outstanding	30,000,000	30,000,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (unaudited) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Licensing and Development	$ 10,847	$ 12,050	$ 32,665	$ 33,754
Operating Expenses:
Depreciation and Amortization	65,680	65,875	197,234	197,770
Professional and Consulting Fees	51,848	30,965	173,274	129,377
Legal Fees	6,225	9,000	21,225	37,357
Research and Development Fees	9,000	9,000	27,000	31,813
Compensation	56,179	48,328	233,035	142,665
Other General and Administrative Expenses	42,514	33,438	147,811	116,112
Total Operating Expenses	231,446	196,606	799,579	655,094
Loss From Operations	(220,599)	(184,556)	(766,914)	(621,340)
Other Income (Expense)
Unrealized Gain (Loss) on Available for Sale Securities (Note G)	3,240	(17,917)	6,096	(160,706)
Realized Gain on Available for Sale Securities (Note G)		27,192		232,937
Other Expense - Change in Warrants Liability (Note D)			(1,196,612)
Forgiveness on Payables (Note H)		121,503		121,503
Settlement Expense				(17,693)
Other Income (Expense), net	3,240	130,778	(1,190,516)	176,041
Net Loss	(217,359)	(53,778)	(1,957,430)	(445,299)
Net Loss Attributable to Common Stockholders	$ (217,359)	$ (53,778)	$ (1,957,430)	$ (445,299)
Weighted Average Outstanding Shares - basic and diluted (in shares)	271,718,989	266,052,322	271,052,322	265,163,433
Net Loss Per Share - basic and diluted (in dollars per share)	$ (0.0008)	$ (0.0002)	$ (0.0072)	$ (0.0017)

XML 14 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (unaudited) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities:
Net Loss	$ (1,957,430)	$ (445,299)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock-based Compensation for Employees	102,233	11,512
Stock-based Compensation for Directors and Consultants	73,698	39,700
Realized Gain on Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G)		(232,937)
Unrealized (Gain) Loss on Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G)	(6,096)	160,706
Increase in Warrants Liability (Note D)	1,196,612
Depreciation and Amortization	197,234	197,770
Decrease in Accounts Receivable		1,969
Decrease in Deferred Revenue	(32,541)	(32,541)
Increase (Decrease) in Accounts Payable - Trade	102,533	(98,639)
Forgiveness on Accounts Payable - Trade		(121,503)
Increase in Available for Sale Securities		(1,294)
Net Cash Used in Operating Activities	(323,757)	(520,556)
Cash Flows From Investing Activities:
Proceeds from Sale of Available for Sale Securities (Note G)		331,465
Net Cash Provided by Investing Activities		331,465
Cash Flows From Financing Activities:
Proceeds from Common Stock Issuance	90,000	120,000
Proceeds from Series C Preferred Stock Issuance		568,000
Net Cash Provided by Financing Activities	90,000	688,000
Net (Decrease) Increase in Cash	(233,757)	498,909
Cash, at Beginning of Period	417,208	7,642
Cash, at End of Period	$ 183,451	$ 506,551

XML 15 R6.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2016
Accounting Policies [Abstract]
BASIS OF PRESENTATION	Note A - BASIS OF PRESENTATION Health Discovery Corporation (the “Company”) is a biotechnology-oriented company that has acquired patents and has patent pending applications for certain machine learning tools, primarily pattern recognition techniques using advanced mathematical algorithms to analyze large amounts of data thereby uncovering patterns that might otherwise be undetectable. Such machine learning tools are currently in use for diagnostics and drug discovery, but are also marketed for other applications. The Company licenses the use of its patent protected technology and may provide services to develop specific learning tools under development agreements or to sell to third parties. The accounting principles followed by the Company and the methods of applying these principles conform with accounting principles generally accepted in the United States of America (GAAP). In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts in the financial statements. Actual results could differ significantly from those estimates. The interim financial statements included in this report are unaudited but reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial position and results of operations for the interim periods presented. All such adjustments are of a normal recurring nature. The results of operations for the nine month period ended September 30, 2016 are not necessarily indicative of the results of a full year’s operations and should be read in conjunction with the financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

XML 16 R7.htm IDEA: XBRL DOCUMENT

REVENUE RECOGNITION	9 Months Ended
REVENUE RECOGNITION	Sep. 30, 2016
Deferred Revenue Disclosure [Abstract]
REVENUE RECOGNITION	Note B – REVENUE RECOGNITION Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements. These arrangements are generally governed by contracts that dictate responsibilities and payment terms. The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled. If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed. The Company treats the incremental direct cost of revenue arrangements, which consists principally of employee bonuses, as deferred charges and these incremental direct costs are amortized to expense using the straight-line method over the same term as the related deferred revenue recognition. Deferred revenue represents the unearned portion of payments received in advance for licensing and development agreements. The Company had total unearned revenue of $115,700 as of September 30, 2016. Unearned revenue of $43,388 is recorded as current and $72,312 is classified as long-term.

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

XML 17 R8.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE	9 Months Ended
NET LOSS PER SHARE	Sep. 30, 2016
Earnings Per Share [Abstract]
NET LOSS PER SHARE	Note C - NET (LOSS) INCOME PER SHARE Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss in all periods presented, potentially dilutive shares are not included in the calculation of diluted EPS, as those shares would create an anti-dilutive result.

XML 18 R9.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS

Note D - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS

Exercise Prices	Number Outstanding		Weighted- Average Remaining Contractual Life (years)		Number Exercisable		Weighted Average Remaining Contractual Life (years) of Exercisable Options and Warrants
$0.027		3,000,000		6.75		3,000,000		6.75
$0.030		72,000,000		9.25		68,250,000		9.25
$0.035		9,000,000		9.75		3,000,000		9.75
$0.036		7,750,000		7.00		6,833,335		7.00
$0.040		1,000,000		1.25		1,000,000		1.25
$0.050		1,000,000		1.25		1,000,000		1.25
$0.060		7,000,000		9.50		7,000,000		9.50
Total		100,750,000				90,083,335

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 19 R10.htm IDEA: XBRL DOCUMENT

PATENTS

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

PATENTS

Note E - PATENTS

XML 20 R11.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY	9 Months Ended
STOCKHOLDERS' EQUITY	Sep. 30, 2016
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	Note F – STOCKHOLDERS’ EQUITY *Series C Preferred Stock* In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2015, the Company had issued a total of 30,000,000 preferred shares. The Series C Preferred Shares were fully subscribed in the third quarter of 2015. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire. The fair value of each warrant granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%. The aggregate fair value of these warrants is $656,380. The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies. Each share of Series C Preferred Stock may be converted into one share of Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. If the Company were to be dissolved, the Series C Preferred Stock receives preferential treatment over Common Stock. During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of September 30, 2016, 7,000,000 shares of this offering have been sold. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days or the warrants will expire. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days or the warrants will expire. The fair value of each warrant granted is $0.0219 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.67%, an expected life of 5 years, and volatility of 96%.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

INVESTMENT IN AVAILABLE FOR SALE SECURITIES

9 Months Ended

Sep. 30, 2016

Available-For-Sale Securities [Abstract]

INVESTMENT IN AVAILABLE FOR SALE SECURITIES

Note G – INVESTMENT IN AVAILABLE FOR SALE SECURITIES

As of September 30, 2016 and December 31, 2015, the Company held 18,000 shares of NeoGenomics stock.

XML 22 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Note H – COMMITMENTS AND CONTINGENCIES

XML 23 R14.htm IDEA: XBRL DOCUMENT

FINANCIAL CONDITION AND GOING CONCERN

9 Months Ended

Sep. 30, 2016

Financial Condition And Going Concern [Abstract]

FINANCIAL CONDITION AND GOING CONCERN

Note I – FINANCIAL CONDITION AND GOING CONCERN

Additionally, the Company is attempting to encourage the Series C Preferred Stockholders to exercise some or all of their warrants in order to help fund the operations of the Company.

While the Company believes these efforts will create a profitable future, there is no guarantee the Company will be successful in these efforts.

XML 24 R15.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Sep. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	Note J – RECENT ACCOUNTING PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards (“ASU”) 2016-02, Leases. This standard update was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including for operating leases, on the balance sheet and disclosing key information about leasing arrangements. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that adopting ASU 2016-02 will have on its financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. This standard update provides guidance for balance sheet classification of deferred taxes. This standard requires that deferred tax assets and liabilities be classified as non-current on the balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount on the balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual period. The Company is currently evaluating the impact that adopting ASU 2015-17 will have on its financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 25 R16.htm IDEA: XBRL DOCUMENT

ACCOUNTING POLICIES	9 Months Ended
ACCOUNTING POLICIES	Sep. 30, 2016
Accounting Policies [Abstract]
ACCOUNTING POLICIES	Note K –ACCOUNTING POLICIES *Patents* Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of September 30, 2016, the Company does not believe there has been any impairment of its patents. *Stock-based Compensation* Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model. Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates. Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule. Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility. Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.

XML 26 R17.htm IDEA: XBRL DOCUMENT

ACCOUNTING POLICIES (Policies)	9 Months Ended
ACCOUNTING POLICIES (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Patents	*Patents* Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of September 30, 2016, the Company does not believe there has been any impairment of its patents.
Stock-based Compensation	*Stock-based Compensation* Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model. Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates. Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule. Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility. Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards (“ASU”) 2016-02, Leases. This standard update was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including for operating leases, on the balance sheet and disclosing key information about leasing arrangements. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that adopting ASU 2016-02 will have on its financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. This standard update provides guidance for balance sheet classification of deferred taxes. This standard requires that deferred tax assets and liabilities be classified as non-current on the balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount on the balance sheet. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Earlier application is permitted as of the beginning of an interim or annual period. The Company is currently evaluating the impact that adopting ASU 2015-17 will have on its financial statements.

XML 27 R18.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of stock option and warrants outstanding by exercise price range

Exercise Prices	Number Outstanding		Weighted- Average Remaining Contractual Life (years)		Number Exercisable		Weighted Average Remaining Contractual Life (years) of Exercisable Options and Warrants
$0.027		3,000,000		6.75		3,000,000		6.75
$0.030		72,000,000		9.25		68,250,000		9.25
$0.035		9,000,000		9.75		3,000,000		9.75
$0.036		7,750,000		7.00		6,833,335		7.00
$0.040		1,000,000		1.25		1,000,000		1.25
$0.050		1,000,000		1.25		1,000,000		1.25
$0.060		7,000,000		9.50		7,000,000		9.50
Total		100,750,000				90,083,335

XML 28 R19.htm IDEA: XBRL DOCUMENT

REVENUE RECOGNITION (Detail Textuals) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
Total unearned revenue	$ 115,700
Unearned revenue, current	43,388	$ 43,388
Unearned revenue, long term	$ 72,312	$ 104,853

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

XML 29 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	100,750,000
Number Exercisable	90,083,335
Stock option and warrant \| Exercise Price $0.027
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.027
Number Outstanding	3,000,000
Weighted-Average Remaining Contractual Life (years)	6 years 9 months
Number Exercisable	3,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	6 years 9 months
Stock option and warrant \| Exercise Price $0.030
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.030
Number Outstanding	72,000,000
Weighted-Average Remaining Contractual Life (years)	9 years 3 months
Number Exercisable	68,250,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	9 years 3 months
Stock option and warrant \| Exercise Price $0.035
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.035
Number Outstanding	9,000,000
Weighted-Average Remaining Contractual Life (years)	9 years 9 months
Number Exercisable	3,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	9 years 9 months
Stock option and warrant \| Exercise Price $0.036
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.036
Number Outstanding	7,750,000
Weighted-Average Remaining Contractual Life (years)	7 years
Number Exercisable	6,833,335
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	7 years
Stock option and warrant \| Exercise Price $0.040
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.040
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	1 year 3 months
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	1 year 3 months
Stock option and warrant \| Exercise Price $0.050
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.050
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	1 year 3 months
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	1 year 3 months
Stock option and warrant \| Exercise Price $0.060
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices \| $ / shares	$ 0.060
Number Outstanding	7,000,000
Weighted-Average Remaining Contractual Life (years)	9 years 6 months
Number Exercisable	7,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants	9 years 6 months

XML 30 R21.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 08, 2016	May 17, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Mr. Kevin Kowbel
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase		1,500,000
Number of shares vested		250,000
Mr. Henry Kaplan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase		1,500,000
Number of shares vested		250,000
Mr. George McGovern
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase		1,500,000
Number of shares vested		250,000
Mr. William Quirk
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase		1,500,000
Number of shares vested		250,000
Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining vesting periods		3 years
Exercise price of option		$ 0.035
Option expiration date		May 17, 2026
Fair value of each option granted		$ 0.0265
Method used		Black-Scholes pricing model
Dividend yield		0.00%
Risk-free interest rate		1.89%
Expected life		5 years
Volatility rate		102.00%
Aggregate computed value of warrants		$ 158,756
Board of Directors \| Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of each option granted					$ 0.0219
Method used					Black-Scholes pricing model
Dividend yield					0.00%
Risk-free interest rate					1.67%
Expected life					5 years
Volatility rate					96.00%
Chairman of the Board of Directors and CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase		3,000,000
Exercise price of option		$ 0.035
Option expiration date		May 17, 2026
Fair value of each option granted		$ 0.0265
Method used		Black-Scholes pricing model
Dividend yield		0.00%
Risk-free interest rate		1.89%
Expected life		5 years
Volatility rate		102.00%
Aggregate computed value of warrants		$ 79,519
Stock options and warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized cost related to stock option grants			$ 192,993		$ 192,993
Remaining vesting periods					2 years 3 months
Option expiration date	Feb. 08, 2026
Fair value of each option granted	$ 0.0219				$ 0.0219
Method used	Black-Scholes pricing model				Black-Scholes pricing model
Dividend yield	0.00%				0.00%
Risk-free interest rate	1.99%				1.67%
Expected life	5 years				5 years
Volatility rate	96.00%				96.00%
Aggregate computed value of warrants	$ 109,271		656,380		$ 656,380
Stock options and warrants \| Employees, directors, and consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based expense			$ 35,163	$ 17,071	$ 175,931	$ 51,212
Stock options and warrants \| Employees and consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining vesting periods	2 years
Number of option to purchase	5,000,000
Exercise price of option	$ 0.03
Stock options and warrants \| Mark A. Moore, Ph.D.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase	500,000
Stock options and warrants \| Hong Zhang, Ph.D.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option to purchase	1,250,000

XML 31 R22.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals 1) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Feb. 08, 2016	May 17, 2016	Mar. 31, 2016	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock warrant liability			$ 940,812	$ 255,800
Increase in Warrants Liability (Note D)					$ 1,196,612
Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued under private placement					7,000,000
Weighted average exercise price					$ 0.20
Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of each option granted		$ 0.0265
Exercise price of option		$ 0.035
Option expiration date		May 17, 2026
Dividend yield		0.00%
Expected life		5 years
Method used		Black-Scholes pricing model
Risk-free interest rate		1.89%
Volatility rate		102.00%
Warrants and Rights Outstanding		$ 158,756
Remaining vesting periods		3 years
Board of Directors \| Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of each option granted					$ 0.0219
Dividend yield					0.00%
Expected life					5 years
Method used					Black-Scholes pricing model
Risk-free interest rate					1.67%
Volatility rate					96.00%
Shares warrant feature per share (in dollars per share)			$ 0.03
Shares contingency warrant feature per share (in dollars per share)			$ 0.06
Number of share authorized for issuance							7,000,000
Stock issued under private placement					7,000,000
Number of shares sold					3,000,000
Proceeds from shares sold					$ 90,000
Series C Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares issued					30,000,000	30,000,000
Shares warrant feature per share (in dollars per share)						$ 0.03
Shares contingency warrant feature per share (in dollars per share)						$ 0.03
Weighted average exercise price					$ 0.20
Stock options and warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of each option granted	$ 0.0219				$ 0.0219
Option expiration date	Feb. 08, 2026
Dividend yield	0.00%				0.00%
Expected life	5 years				5 years
Method used	Black-Scholes pricing model				Black-Scholes pricing model
Risk-free interest rate	1.99%				1.67%
Volatility rate	96.00%				96.00%
Warrants and Rights Outstanding	$ 109,271				$ 656,380
Remaining vesting periods					2 years 3 months
Option and warrant outstanding					100,750,000
Weighted average exercise price					$ 0.033
Weighted-Average Remaining Contractual Life (years)					9 years 4 months 6 days
Aggregate intrinsic value of outstanding and exercisable options and warrants outstanding and exercisable					$ 392,400
Closing price of outstanding and exercisable options and warrants less exercise prices					$ 0.0351
Increase in Warrants Liability (Note D)			$ 940,812	$ 1,196,612

XML 32 R23.htm IDEA: XBRL DOCUMENT

PATENTS (Detail Textuals) - USD ($)	3 Months Ended		9 Months Ended
PATENTS (Detail Textuals) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and patent related costs, net	$ 744,026		$ 744,026		$ 941,066
Accumulated amortization of patents	3,241,769		3,241,769		$ 3,044,729
Amortization charged on patents	65,680	$ 65,680	197,039	$ 197,039
Estimated amortization expense of patents at 2017	262,720		262,720
Estimated amortization expense of patents at 2018	262,720		262,720
Estimated amortization expense of patents at 2019	262,720		262,720
Estimated amortization expense of patents at 2020	$ 152,906		$ 152,906

XML 33 R24.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Detail Textuals)		9 Months Ended
STOCKHOLDERS' EQUITY (Detail Textuals)	Feb. 08, 2016 USD ($) $ / shares	Sep. 30, 2016 USD ($) $ / shares $ / Warrant shares	Dec. 31, 2015 shares
Stock options and warrants
Class Of Stock [Line Items]
Price per share for exercise of warrants, condition one (in dollars per share)		$ 0.033
Fair value of each option granted	$ 0.0219	$ 0.0219
Method used	Black-Scholes pricing model	Black-Scholes pricing model
Dividend yield	0.00%	0.00%
Risk-free interest rate	1.99%	1.67%
Expected life	5 years	5 years
Volatility rate	96.00%	96.00%
Aggregate computed value of warrants \| $	$ 109,271	$ 656,380
Private placement
Class Of Stock [Line Items]
Preferred shares warrant feature per share (in dollars per share)		$ 0.03
Preferred shares contingency warrant feature per share (in dollars per share)		$ 0.06
Series C preferred stock, contingency warrant exercise description		The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days.
Percentage of warrants exercise if market price for company's common stock is $0.20		50.00%
Price per share for exercise of warrants, condition one (in dollars per share)		$ 0.20
Number of days for common stock price at $0.20		30 days
Percentage of warrants exercise if market price for company's common stock is $0.30		50.00%
Price per share for exercise of warrants, condition two \| $ / Warrant		0.30
Number of days for common stock price at $0.30		30 days
Stock Issued Under Private Placement \| shares		7,000,000
Valuation method for warrants		Black Scholes Method
Series C Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares issued \| shares		30,000,000	30,000,000
Preferred shares warrant feature per share (in dollars per share)		$ 0.03
Preferred shares contingency warrant feature per share (in dollars per share)		$ 0.03
Series C preferred stock, contingency warrant exercise description		The contingency warrants were issued during the three month period ended March 31, 2016 as a result of the Company not attaining profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days.
Price per share for exercise of warrants, condition one (in dollars per share)		$ 0.20
Number of days for common stock price at $0.20		30 days
Percentage of warrants exercise if market price for company's common stock is $0.30		50.00%
Price per share for exercise of warrants, condition two \| $ / Warrant		0.30
Number of days for common stock price at $0.30		30 days
Fair value of exercise price of warrants		$ 0.0219
Valuation method for warrants		Black Scholes Method
Series C Preferred Stock converted into Common Stock \| shares		1

XML 34 R25.htm IDEA: XBRL DOCUMENT

INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Number of shares of Neo Genomics stock held	18,000	18,000
NeoGenomics Laboratories Inc \| Other income (expense)
Schedule of Available-for-sale Securities [Line Items]
Unrealized net gain (loss) on available for sale securities	$ 6,096
NeoGenomics Laboratories Inc \| Carrying value
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities	1,945,000
NeoGenomics Laboratories Inc \| Fair value
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities	$ 148,074

XML 35 R26.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Detail Textuals) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Accrued professional liability			$ 239,910
Increase (Decrease) in accounts payable	$ 121,503
Settlement expense		$ 17,693

XML 36 R27.htm IDEA: XBRL DOCUMENT

FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Financial Condition And Going Concern [Abstract]
Cash	$ 183,451	$ 417,208	$ 506,551	$ 7,642
Schedule of Available-for-sale Securities [Line Items]
Current liabilities	$ 390,191	$ 626,926
Private placement
Schedule of Available-for-sale Securities [Line Items]
Stock issued under private placement	7,000,000
Private placement \| Board of Directors
Schedule of Available-for-sale Securities [Line Items]
Number of share authorized for issuance			7,000,000
Stock issued under private placement	7,000,000
Number of shares sold	3,000,000
Proceeds from shares sold	$ 90,000
NeoGenomics Laboratories Inc \| Fair value
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities	$ 148,074

XML 37 R28.htm IDEA: XBRL DOCUMENT

ACCOUNTING POLICIES (Detail Textuals) - Patents	9 Months Ended
ACCOUNTING POLICIES (Detail Textuals) - Patents	Sep. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Amortization method	Straight-line method
Useful life	17 years

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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‚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end XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 60 141 1 false 26 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.healthdiscoverycorp.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Balance Sheets (unaudited) Sheet http://www.healthdiscoverycorp.com/role/BalanceSheetsUnaudited Balance Sheets (unaudited) Statements 2 false false R3.htm 003 - Statement - Balance Sheets (unaudited) (Parentheticals) Sheet http://www.healthdiscoverycorp.com/role/BalanceSheetsUnauditedParentheticals Balance Sheets (unaudited) (Parentheticals) Statements 3 false false R4.htm 004 - Statement - Statements of Operations (unaudited) Sheet http://www.healthdiscoverycorp.com/role/StatementsOfOperationsUnaudited Statements of Operations (unaudited) Statements 4 false false R5.htm 005 - Statement - Statements of Cash Flows (unaudited) Sheet http://www.healthdiscoverycorp.com/role/StatementsOfCashFlowsUnaudited Statements of Cash Flows (unaudited) Statements 5 false false R6.htm 006 - Disclosure - BASIS OF PRESENTATION Sheet http://www.healthdiscoverycorp.com/role/Basisofpresentation BASIS OF PRESENTATION Notes 6 false false R7.htm 007 - Disclosure - REVENUE RECOGNITION Sheet http://www.healthdiscoverycorp.com/role/RevenueRecognition REVENUE RECOGNITION Notes 7 false false R8.htm 008 - Disclosure - NET LOSS PER SHARE Sheet http://www.healthdiscoverycorp.com/role/NetLossPerShare NET LOSS PER SHARE Notes 8 false false R9.htm 009 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS Sheet http://www.healthdiscoverycorp.com/role/StockBasedCompensationAndOtherEquityBasedPayments STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS Notes 9 false false R10.htm 010 - Disclosure - PATENTS Sheet http://www.healthdiscoverycorp.com/role/Patents PATENTS Notes 10 false false R11.htm 011 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.healthdiscoverycorp.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 11 false false R12.htm 012 - Disclosure - INVESTMENT IN AVAILABLE FOR SALE SECURITIES Sheet http://www.healthdiscoverycorp.com/role/InvestmentInAvailableForSaleSecurities INVESTMENT IN AVAILABLE FOR SALE SECURITIES Notes 12 false false R13.htm 013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.healthdiscoverycorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 014 - Disclosure - FINANCIAL CONDITION AND GOING CONCERN Sheet http://www.healthdiscoverycorp.com/role/FinancialConditionAndGoingConcern FINANCIAL CONDITION AND GOING CONCERN Notes 14 false false R15.htm 015 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.healthdiscoverycorp.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 15 false false R16.htm 016 - Disclosure - ACCOUNTING POLICIES Sheet http://www.healthdiscoverycorp.com/role/CRITICALACCOUNTINGPOLICIES ACCOUNTING POLICIES Notes 16 false false R17.htm 017 - Disclosure - ACCOUNTING POLICIES (Policies) Sheet http://www.healthdiscoverycorp.com/role/CRITICALACCOUNTINGPOLICIESPolicies ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 018 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables) Sheet http://www.healthdiscoverycorp.com/role/STOCKBASEDCOMPENSATIONANDOTHEREQUITYBASEDPAYMENTSTables STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables) Tables http://www.healthdiscoverycorp.com/role/StockBasedCompensationAndOtherEquityBasedPayments 18 false false R19.htm 019 - Disclosure - REVENUE RECOGNITION (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/RevenueRecognitionDetailTextuals REVENUE RECOGNITION (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/RevenueRecognition 19 false false R20.htm 020 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details) Sheet http://www.healthdiscoverycorp.com/role/STOCKBASEDCOMPENSATIONANDOTHEREQUITYBASEDPAYMENTSDetails STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details) Details http://www.healthdiscoverycorp.com/role/STOCKBASEDCOMPENSATIONANDOTHEREQUITYBASEDPAYMENTSTables 20 false false R21.htm 021 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/StockBasedCompensationAndOtherEquityBasedPaymentsDetailTextuals STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/STOCKBASEDCOMPENSATIONANDOTHEREQUITYBASEDPAYMENTSTables 21 false false R22.htm 022 - Disclosure - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals 1) Sheet http://www.healthdiscoverycorp.com/role/STOCKBASEDCOMPENSATIONANDOTHEREQUITYBASEDPAYMENTSDetails2 STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals 1) Details http://www.healthdiscoverycorp.com/role/STOCKBASEDCOMPENSATIONANDOTHEREQUITYBASEDPAYMENTSTables 22 false false R23.htm 023 - Disclosure - PATENTS (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/PATENTSDetailTextuals PATENTS (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/Patents 23 false false R24.htm 024 - Disclosure - STOCKHOLDERS' EQUITY (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/STOCKHOLDERSEQUITYDetailTextuals STOCKHOLDERS' EQUITY (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/StockholdersEquity 24 false false R25.htm 025 - Disclosure - INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/InvestmentInAvailableForSaleSecuritiesDetailTextuals INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/InvestmentInAvailableForSaleSecurities 25 false false R26.htm 026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/CommitmentsAndContingenciesDetailTextuals COMMITMENTS AND CONTINGENCIES (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/CommitmentsAndContingencies 26 false false R27.htm 027 - Disclosure - FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/FinancialConditionAndGoingConcernDetailTextuals FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/FinancialConditionAndGoingConcern 27 false false R28.htm 028 - Disclosure - ACCOUNTING POLICIES (Detail Textuals) Sheet http://www.healthdiscoverycorp.com/role/CRITICALACCOUNTINGPOLICIESDetailTextuals ACCOUNTING POLICIES (Detail Textuals) Details http://www.healthdiscoverycorp.com/role/CRITICALACCOUNTINGPOLICIESPolicies 28 false false All Reports Book All Reports hdvy-20160930.xml hdvy-20160930.xsd hdvy-20160930_cal.xml hdvy-20160930_def.xml hdvy-20160930_lab.xml hdvy-20160930_pre.xml true true ZIP 44 0001571049-16-020055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-16-020055-xbrl.zip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end